https://rpubs.com/alex_istrate/526483
Am folosit Microsot Excel 2016 pentru managementul bazei de date. Pentru toate analizele statistice și graficele ulterioare am folosit R 3.6.0. Am considerat p < 0.05 ca fiind semnificativ statistic și p < 0.1 ca prezentând doar o tendință spre semnificativitate statistică.
Factor | Detalis | Total | Pre | Post | Statistics |
Examination | 60 | 30 (50.0%) | 30 (50.0%) | ||
Weight (g) | M (min:max) | 243.5 (193:296) | 237.5 (210:280) | 249.5 (193:296) | Paired T-test: p=0.008 |
μ ±DS | 240.90 ±19.2 | 234.93 ±16.4 | 246.87 ±20.2 | ||
EDV | M (min:max) | 5.73 (3.24:7.52) | 5.8 (3.24:7.1) | 5.65 (4.52:7.52) | Paired T-test: p=0.579 |
μ ±DS | 5.77 ±0.785 | 5.73 ±0.746 | 5.83 ±0.837 | ||
ESV | M (min:max) | 3.7 (1.11:61.67) | 3.67 (1.11:61.67) | 3.7 (2.58:5.95) | Wilcoxon paired test: p=0.732 |
μ ±DS | 5.69 ±10.3 | 7.32 ±14.0 | 3.89 ±0.935 | ||
EF(M) | M (min:max) | 70.67 (43:95.67) | 70.83 (45:95.67) | 69.67 (43:83) | Paired T-test: p=0.547 |
μ ±DS | 69.10 ±10.7 | 70.04 ±11.2 | 68.05 ±10.3 | ||
SF(M) | M (min:max) | 35.3 (18.45:65.76) | 37.08 (19.38:65.76) | 34.66 (18.45:46.79) | Wilcoxon paired test: p=0.578 |
μ ±DS | 35.09 ±8.49 | 36.20 ±9.44 | 33.85 ±7.28 | ||
EDV(S) | M (min:max) | 0.17 (0.07:0.32) | 0.15 (0.07:0.32) | 0.18 (0.08:0.28) | Paired T-test: p=0.236 |
μ ±DS | 0.172 ±0.059 | 0.163 ±0.0678 | 0.183 ±0.0462 | ||
ESV(S) | M (min:max) | 0.04 (0.01:0.6) | 0.04 (0.01:0.6) | 0.05 (0.03:0.09) | Wilcoxon paired test: p=0.135 |
μ ±DS | 0.058 ±0.078 | 0.0629 ±0.107 | 0.0525 ±0.0167 | ||
EF(A2C) | M (min:max) | 73.46 (47.84:87.62) | 77.53 (47.84:87.62) | 71.22 (54.78:84.27) | Paired T-test: p=0.130 |
μ ±DS | 72.71 ±8.32 | 74.15 ±9.81 | 71.10 ±6.04 | ||
μ ±DS = Mean (standard deviation); M (min:max) = Median (min:max); MW = Mann-WhitneyTest; OR/RR = odds-ratio / risc-ratio [95% CI] and p value from Fisher test); V = Cramer V (p value from Chi² test); |
Table 1: Summary statistics: NT-proBNP (pg/mL).
NT-proBNP (pg/mL) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: NT-proBNP (pg/mL) (Shapiro-Wilk normality test: p=0.130) | |||
(total) | 39 (100.0%) | 435.92 ±129.9 | 432.3 (245.1:800.9) |
Grup: Group (ANOVA: p=0.162) | |||
before treatment | 14 (35.9%) | 407.25 ±120.7 | 377.7 (245.1:659.1) |
control | 8 (20.5%) | 377.83 ±114.0 | 355.1 (258.6:579.5) |
50mg DFP | 7 (17.9%) | 469.05 ±87.3 | 488.4 (372.5:586.9) |
100mg DFP | 10 (25.6%) | 499.34 ±159.5 | 435.8 (282.9:800.9) |
Figure 1: Box & violon plots of NT-proBNP (pg/mL) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 2: ANOVA model: NT-proBNP (pg/mL).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 86 408.7 | 1.816 | 0.162 |
Group: untreated vs. treated | 1 | 78 221.9 | 4.931 | 0.033 * |
Group: before treatment vs. control | 1 | 4 408.4 | 0.278 | 0.601 |
Group: 50 vs. 100 mg DFP | 1 | 3 778.4 | 0.238 | 0.629 |
Residuals | 35 | 555 186.7 |
|
Figure 2: Box & violon plots of NT-proBNP (pg/mL) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 3: ANOVA model: NT-proBNP (pg/mL).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 86 408.7 | 1.816 | 0.162 |
Group: no HF vs. HF | 1 | 17 948.7 | 1.132 | 0.295 |
Group: control vs. treated | 1 | 64 681.7 | 4.078 | 0.051 . |
Group: 50 vs. 100 mg DFP | 1 | 3 778.4 | 0.238 | 0.629 |
Residuals | 35 | 555 186.7 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 10) = 286.63 | 0.97 | <0.001 | F(1, 22) = 792.30 | 0.97 | <0.001 | F(1, 27) = 43 005.65 | 1.00 | <0.001 | F(1, 22) = 792.30 | 0.97 | <0.001 |
Group | F(2, 10) = 0.81 | 0.14 | 0.472 | F(2, 22) = 1.75 | 0.14 | 0.197 | F(2, 27) = 2.49 | 0.16 | 0.101 | F(2, 22) = 1.75 | 0.14 | 0.197 |
Examination | F(1, 10) = 5.64 | 0.36 | 0.039 | F(1, 22) = 4.15 | 0.16 | 0.054 | F(1, 27) = 1.34 | 0.05 | 0.257 | F(1, 22) = 4.15 | 0.16 | 0.054 |
Group:Examination | F(2, 10) = 1.23 | 0.20 | 0.332 | F(2, 22) = 3.81 | 0.26 | 0.038 | F(2, 27) = 5.80 | 0.30 | 0.008 | F(2, 22) = 3.81 | 0.26 | 0.038 |
Figure 1: Box & violon plots of NT-proBNP (pg/mL) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 346.71 (NA) | 346.71 (NA) | 346.71 (346.71, 346.71) |
Post | 377.83 (113.95) | 363.62 (1.34) | 355.06 (258.64, 579.47) | |
p-value: | 0.488 | 0.319 | ||
p-value (imputed): | 0.650 | 0.650 | ||
50mg DFP | Pre | 523.09 (85.20) | 517.92 (1.17) | 485.66 (455.75, 659.09) |
Post | 469.05 (87.28) | 462.01 (1.21) | 488.45 (372.47, 586.88) | |
p-value: | 0.980 | 0.688 | ||
p-value (imputed): | 0.770 | 0.770 | ||
100mg DFP | Pre | 342.43 (89.53) | 333.59 (1.27) | 305.30 (245.07, 534.28) |
Post | 499.34 (159.54) | 477.16 (1.37) | 435.80 (282.93, 800.87) | |
p-value: | 0.020 | 0.002 | ||
p-value (imputed): | 0.003 | 0.003 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 407.25 (120.74) | 391.42 (1.34) | 377.66 (245.07, 659.09) | |
control | 346.71 (NA) | 346.71 (NA) | 346.71 (346.71, 346.71) | ||
50mg DFP | 523.09 (85.20) | 517.92 (1.17) | 485.66 (455.75, 659.09) | ||
100mg DFP | 342.43 (89.53) | 333.59 (1.27) | 305.30 (245.07, 534.28) | ||
p-value: | control vs. 50mg DFP | 0.567 | 0.396 | ||
p-value (imputed): | control vs. 50mg DFP | 0.557 | 0.557 | ||
p-value: | control vs. 100mg DFP | 0.999 | 0.222 | ||
p-value (imputed): | control vs. 100mg DFP | 0.628 | 0.628 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.155 | 0.012 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.129 | 0.129 | ||
Post | (overall) | 451.98 (134.50) | 433.49 (1.34) | 435.10 (258.64, 800.87) | |
control | 377.83 (113.95) | 363.62 (1.34) | 355.06 (258.64, 579.47) | ||
50mg DFP | 469.05 (87.28) | 462.01 (1.21) | 488.45 (372.47, 586.88) | ||
100mg DFP | 499.34 (159.54) | 477.16 (1.37) | 435.80 (282.93, 800.87) | ||
p-value: | control vs. 50mg DFP | 0.977 | 0.152 | ||
p-value (imputed): | control vs. 50mg DFP | 0.200 | 0.200 | ||
p-value: | control vs. 100mg DFP | 0.958 | 0.037 | ||
p-value (imputed): | control vs. 100mg DFP | 0.039 | 0.039 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.994 | 0.794 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.816 | 0.816 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 7: Summary statistics: Hepcidin (ng/mL).
Hepcidin (ng/mL) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: Hepcidin (ng/mL) (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 39 (100.0%) | 29.43 ±14.1 | 26.5 (14.5:80.4) |
Grup: Group (Kruskal-Wallis rank sum test: p=0.380) | |||
before treatment | 14 (35.9%) | 29.35 ±13.7 | 23.8 (16.0:64.1) |
control | 8 (20.5%) | 36.56 ±22.3 | 35.8 (14.6:80.4) |
50mg DFP | 7 (17.9%) | 21.08 ±4.1 | 21.1 (14.6:27.4) |
100mg DFP | 10 (25.6%) | 29.66 ±8.4 | 31.1 (14.5:39.4) |
Figure 3: Box & violon plots of Hepcidin (ng/mL) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 8: ANOVA model: Hepcidin (ng/mL).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 895.1 | 1.564 | 0.215 |
Group: untreated vs. treated | 1 | 327.3 | 1.716 | 0.199 |
Group: no HF vs. no control | 1 | 264.8 | 1.388 | 0.247 |
Group: 50 vs. 100 mg DFP | 1 | 303.0 | 1.588 | 0.216 |
Residuals | 35 | 6 676.6 |
|
Figure 4: Box & violon plots of Hepcidin (ng/mL) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 9: ANOVA model: Hepcidin (ng/mL).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 895.1 | 1.564 | 0.215 |
Group: no HF vs. HF | 1 | 0.1 | 0.001 | 0.980 |
Group: control vs. treated | 1 | 592.0 | 3.104 | 0.087 . |
Group: 50 vs. 100 mg DFP | 1 | 303.0 | 1.588 | 0.216 |
Residuals | 35 | 6 676.6 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 10) = 270.42 | 0.96 | <0.001 | F(1, 22) = 323.52 | 0.94 | <0.001 | F(1, 27) = 5 700.18 | 1.00 | <0.001 | F(1, 22) = 323.52 | 0.94 | <0.001 |
Group | F(2, 10) = 7.16 | 0.59 | 0.012 | F(2, 22) = 4.30 | 0.28 | 0.027 | F(2, 27) = 4.13 | 0.23 | 0.027 | F(2, 22) = 4.30 | 0.28 | 0.027 |
Examination | F(1, 10) = 0.16 | 0.02 | 0.697 | F(1, 22) = 0.00 | <0.01 | 0.957 | F(1, 27) = 0.00 | <0.01 | 0.963 | F(1, 22) = 0.00 | <0.01 | 0.957 |
Group:Examination | F(2, 10) = 0.49 | 0.09 | 0.624 | F(2, 22) = 0.55 | 0.05 | 0.586 | F(2, 27) = 0.21 | 0.02 | 0.811 | F(2, 22) = 0.55 | 0.05 | 0.586 |
Figure 3: Box & violon plots of Hepcidin (ng/mL) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 47.10 (NA) | 47.10 (NA) | 47.10 (47.10, 47.10) |
Post | 36.56 (22.33) | 31.12 (1.84) | 35.76 (14.61, 80.42) | |
p-value: | 0.364 | 0.663 | ||
p-value (imputed): | 0.418 | 0.418 | ||
50mg DFP | Pre | 19.05 (2.23) | 18.94 (1.13) | 19.43 (16.03, 21.73) |
Post | 21.08 (4.08) | 20.74 (1.22) | 21.14 (14.61, 27.43) | |
p-value: | 0.767 | 0.966 | ||
p-value (imputed): | 0.761 | 0.761 | ||
100mg DFP | Pre | 33.57 (14.37) | 31.30 (1.48) | 31.59 (19.00, 64.09) |
Post | 29.66 (8.39) | 28.36 (1.40) | 31.13 (14.50, 39.37) | |
p-value: | 0.705 | 0.637 | ||
p-value (imputed): | 0.577 | 0.577 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 29.35 (13.74) | 26.93 (1.51) | 23.81 (16.03, 64.09) | |
control | 47.10 (NA) | 47.10 (NA) | 47.10 (47.10, 47.10) | ||
50mg DFP | 19.05 (2.23) | 18.94 (1.13) | 19.43 (16.03, 21.73) | ||
100mg DFP | 33.57 (14.37) | 31.30 (1.48) | 31.59 (19.00, 64.09) | ||
p-value: | control vs. 50mg DFP | 0.042 | 0.267 | ||
p-value (imputed): | control vs. 50mg DFP | 0.358 | 0.358 | ||
p-value: | control vs. 100mg DFP | 0.410 | 0.891 | ||
p-value (imputed): | control vs. 100mg DFP | 0.977 | 0.977 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.050 | 0.115 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.236 | 0.236 | ||
Post | (overall) | 29.47 (14.60) | 26.76 (1.55) | 27.43 (14.50, 80.42) | |
control | 36.56 (22.33) | 31.12 (1.84) | 35.76 (14.61, 80.42) | ||
50mg DFP | 21.08 (4.08) | 20.74 (1.22) | 21.14 (14.61, 27.43) | ||
100mg DFP | 29.66 (8.39) | 28.36 (1.40) | 31.13 (14.50, 39.37) | ||
p-value: | control vs. 50mg DFP | 0.508 | 0.112 | ||
p-value (imputed): | control vs. 50mg DFP | 0.040 | 0.040 | ||
p-value: | control vs. 100mg DFP | 0.989 | 0.903 | ||
p-value (imputed): | control vs. 100mg DFP | 0.444 | 0.444 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.190 | 0.251 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.316 | 0.316 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 10: Summary statistics: Serum Iron (μg/L).
Serum Iron (μg/L) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: Serum Iron (μg/L) (Shapiro-Wilk normality test: p<0.001) | |||
(total) | 38 (100.0%) | 5.65 ±1.5 | 5.3 (4.0:11.9) |
Grup: Group (Kruskal-Wallis rank sum test: p=0.016) | |||
before treatment | 13 (34.2%) | 5.63 ±1.3 | 5.5 (4.0:9.0) |
control | 8 (21.1%) | 4.61 ±0.3 | 4.5 (4.2:5.1) |
50mg DFP | 7 (18.4%) | 5.92 ±1.6 | 5.3 (4.2:8.2) |
100mg DFP | 10 (26.3%) | 6.33 ±2.0 | 5.8 (4.9:11.9) |
Figure 5: Box & violon plots of Serum Iron (μg/L) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 11: ANOVA model: Serum Iron (μg/L).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 13.8 | 2.173 | 0.109 |
Group: untreated vs. treated | 1 | 8.0 | 3.770 | 0.060 . |
Group: no HF vs. no control | 1 | 5.1 | 2.407 | 0.130 |
Group: 50 vs. 100 mg DFP | 1 | 0.7 | 0.342 | 0.563 |
Residuals | 34 | 72.1 |
|
Figure 6: Box & violon plots of Serum Iron (μg/L) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 12: ANOVA model: Serum Iron (μg/L).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 13.8 | 2.173 | 0.109 |
Group: no HF vs. HF | 1 | 0.0 | 0.006 | 0.937 |
Group: control vs. treated | 1 | 13.1 | 6.171 | 0.018 * |
Group: 50 vs. 100 mg DFP | 1 | 0.7 | 0.342 | 0.563 |
Residuals | 34 | 72.1 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 9) = 255.14 | 0.97 | <0.001 | F(1, 22) = 932.24 | 0.98 | <0.001 | F(1, 27) = 5 256.07 | 0.99 | <0.001 | F(1, 22) = 932.24 | 0.98 | <0.001 |
Group | F(2, 9) = 1.33 | 0.23 | 0.312 | F(2, 22) = 3.23 | 0.23 | 0.059 | F(2, 27) = 4.31 | 0.24 | 0.024 | F(2, 22) = 3.23 | 0.23 | 0.059 |
Examination | F(1, 9) = 0.35 | 0.04 | 0.571 | F(1, 22) = 0.01 | <0.01 | 0.939 | F(1, 27) = 0.00 | <0.01 | 0.986 | F(1, 22) = 0.01 | <0.01 | 0.939 |
Group:Examination | F(2, 9) = 0.03 | <0.01 | 0.966 | F(2, 22) = 1.49 | 0.12 | 0.248 | F(2, 27) = 2.26 | 0.14 | 0.124 | F(2, 22) = 1.49 | 0.12 | 0.248 |
Figure 5: Box & violon plots of Serum Iron (μg/L) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 4.34 (NA) | 4.34 (NA) | 4.34 (4.34, 4.34) |
Post | 4.61 (0.30) | 4.60 (1.07) | 4.52 (4.17, 5.10) | |
p-value: | 0.961 | 0.094 | ||
p-value (imputed): | 0.157 | 0.157 | ||
50mg DFP | Pre | 5.17 (1.02) | 5.09 (1.22) | 5.34 (4.00, 6.51) |
Post | 5.92 (1.57) | 5.75 (1.29) | 5.33 (4.20, 8.18) | |
p-value: | 0.865 | 0.318 | ||
p-value (imputed): | 0.549 | 0.549 | ||
100mg DFP | Pre | 6.13 (1.41) | 6.01 (1.23) | 6.02 (4.73, 9.04) |
Post | 6.33 (2.00) | 6.13 (1.28) | 5.84 (4.88, 11.88) | |
p-value: | 0.551 | 0.498 | ||
p-value (imputed): | 0.504 | 0.504 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 5.63 (1.31) | 5.50 (1.24) | 5.52 (4.00, 9.04) | |
control | 4.34 (NA) | 4.34 (NA) | 4.34 (4.34, 4.34) | ||
50mg DFP | 5.17 (1.02) | 5.09 (1.22) | 5.34 (4.00, 6.51) | ||
100mg DFP | 6.13 (1.41) | 6.01 (1.23) | 6.02 (4.73, 9.04) | ||
p-value: | control vs. 50mg DFP | 0.835 | 0.980 | ||
p-value (imputed): | control vs. 50mg DFP | 0.994 | 0.994 | ||
p-value: | control vs. 100mg DFP | 0.613 | 0.488 | ||
p-value (imputed): | control vs. 100mg DFP | 0.660 | 0.660 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.819 | 0.378 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.749 | 0.749 | ||
Post | (overall) | 5.67 (1.65) | 5.49 (1.27) | 5.13 (4.17, 11.88) | |
control | 4.61 (0.30) | 4.60 (1.07) | 4.52 (4.17, 5.10) | ||
50mg DFP | 5.92 (1.57) | 5.75 (1.29) | 5.33 (4.20, 8.18) | ||
100mg DFP | 6.33 (2.00) | 6.13 (1.28) | 5.84 (4.88, 11.88) | ||
p-value: | control vs. 50mg DFP | 0.811 | 0.064 | ||
p-value (imputed): | control vs. 50mg DFP | 0.118 | 0.118 | ||
p-value: | control vs. 100mg DFP | 0.475 | 0.004 | ||
p-value (imputed): | control vs. 100mg DFP | 0.015 | 0.015 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.635 | 0.554 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.773 | 0.773 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 13: Summary statistics: Mitochondrial Feritin (ng/mg protein).
Mitochondrial Feritin (ng/mg protein) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: Mitochondrial Feritin (ng/mg protein) (Shapiro-Wilk normality test: p=0.010) | |||
(total) | 19 (100.0%) | 0.88 ±0.3 | 0.8 (0.5:1.8) |
Grup: Group (Kruskal-Wallis rank sum test: p=0.121) | |||
control | 6 (31.6%) | 0.89 ±0.5 | 0.7 (0.5:1.8) |
50mg DFP | 5 (26.3%) | 1.12 ±0.3 | 1.3 (0.7:1.5) |
100mg DFP | 8 (42.1%) | 0.73 ±0.1 | 0.6 (0.6:0.9) |
Figure 7: Box & violon plots of Mitochondrial Feritin (ng/mg protein) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 14: ANOVA model: Mitochondrial Feritin (ng/mg protein).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 2 | 0.5 | 2.315 | 0.131 |
Group: control vs. treated | 1 | 0.0 | 0.007 | 0.934 |
Group: 50 vs. 100 mg DFP | 1 | 0.5 | 4.624 | 0.047 * |
Residuals | 16 | 1.7 |
|
Table 15: Summary statistics: IL-6 (pg/mg protein).
IL-6 (pg/mg protein) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: IL-6 (pg/mg protein) (Shapiro-Wilk normality test: p=0.307) | |||
(total) | 19 (100.0%) | 265.16 ±72.2 | 246.3 (153.3:436.1) |
Grup: Group (ANOVA: p=0.001) | |||
control | 6 (31.6%) | 339.20 ±64.5 | 320.0 (263.9:436.1) |
50mg DFP | 5 (26.3%) | 254.70 ±32.9 | 246.3 (215.5:304.8) |
100mg DFP | 8 (42.1%) | 216.16 ±48.0 | 210.8 (153.3:314.5) |
Figure 8: Box & violon plots of IL-6 (pg/mg protein) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 16: ANOVA model: IL-6 (pg/mg protein).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 2 | 52 645.2 | 10.210 | 0.001 ** |
Group: control vs. treated | 1 | 48 073.1 | 18.647 | <0.001 *** |
Group: 50 vs. 100 mg DFP | 1 | 4 572.1 | 1.773 | 0.202 |
Residuals | 16 | 41 250.0 |
|
Table 17: Summary statistics: TNF-α (pg/mg protein).
TNF-α (pg/mg protein) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: TNF-α (pg/mg protein) (Shapiro-Wilk normality test: p=0.319) | |||
(total) | 19 (100.0%) | 105.69 ±32.0 | 99.7 (42.5:158.4) |
Grup: Group (ANOVA: p=0.097) | |||
control | 6 (31.6%) | 125.31 ±31.8 | 136.3 (85.2:158.4) |
50mg DFP | 5 (26.3%) | 109.23 ±18.1 | 102.3 (90.8:131.4) |
100mg DFP | 8 (42.1%) | 88.75 ±32.6 | 88.1 (42.5:135.9) |
Figure 9: Box & violon plots of TNF-α (pg/mg protein) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 18: ANOVA model: TNF-α (pg/mg protein).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 2 | 4 670.1 | 2.704 | 0.097 . |
Group: control vs. treated | 1 | 3 378.5 | 3.912 | 0.065 . |
Group: 50 vs. 100 mg DFP | 1 | 1 291.6 | 1.496 | 0.239 |
Residuals | 16 | 13 816.8 |
|
Table 19: Summary statistics: Tissue Iron (μg/mg protein).
Tissue Iron (μg/mg protein) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: Tissue Iron (μg/mg protein) (Shapiro-Wilk normality test: p=0.029) | |||
(total) | 19 (100.0%) | 0.80 ±0.3 | 0.7 (0.4:1.5) |
Grup: Group (Kruskal-Wallis rank sum test: p=0.915) | |||
control | 6 (31.6%) | 0.80 ±0.3 | 0.7 (0.6:1.4) |
50mg DFP | 5 (26.3%) | 0.83 ±0.3 | 0.8 (0.5:1.3) |
100mg DFP | 8 (42.1%) | 0.78 ±0.4 | 0.7 (0.4:1.5) |
Figure 10: Box & violon plots of Tissue Iron (μg/mg protein) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 20: ANOVA model: Tissue Iron (μg/mg protein).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 2 | 0.0 | 0.032 | 0.968 |
Group: control vs. treated | 1 | 0.0 | 0.001 | 0.976 |
Group: 50 vs. 100 mg DFP | 1 | 0.0 | 0.064 | 0.804 |
Residuals | 16 | 1.7 |
|
Table 21: Summary statistics: EF(M).
EF(M) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: EF(M) (Shapiro-Wilk normality test: p=0.533) | |||
(total) | 57 (100.0%) | 69.10 ±10.7 | 70.7 (43.0:95.7) |
Grup: Group (ANOVA: p=0.221) | |||
before induction | 30 (52.6%) | 70.04 ±11.2 | 70.8 (45.0:95.7) |
control | 9 (15.8%) | 70.92 ±7.7 | 74.0 (57.3:80.0) |
50mg DFP | 8 (14.0%) | 61.75 ±13.5 | 60.7 (43.0:77.7) |
100mg DFP | 10 (17.5%) | 70.50 ±7.9 | 69.5 (57.3:83.0) |
Figure 11: Box & violon plots of EF(M) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 22: ANOVA model: EF(M).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 508.2 | 1.515 | 0.221 |
Group: untreated vs. treated | 1 | 162.7 | 1.455 | 0.233 |
Group: no HF vs. no control | 1 | 5.3 | 0.047 | 0.829 |
Group: 50 vs. 100 mg DFP | 1 | 340.3 | 3.043 | 0.087 . |
Residuals | 53 | 5 926.8 |
|
Figure 12: Box & violon plots of EF(M) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 23: ANOVA model: EF(M).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 508.2 | 1.515 | 0.221 |
Group: no HF vs. HF | 1 | 56.7 | 0.507 | 0.479 |
Group: control vs. treated | 1 | 111.2 | 0.995 | 0.323 |
Group: 50 vs. 100 mg DFP | 1 | 340.3 | 3.043 | 0.087 . |
Residuals | 53 | 5 926.8 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 24) = 3 996.55 | 0.99 | <0.001 | F(1, 24) = 3 996.55 | 0.99 | <0.001 | F(1, 27) = 76 865.70 | 1.00 | <0.001 | F(1, 24) = 3 996.55 | 0.99 | <0.001 |
Group | F(2, 24) = 2.26 | 0.16 | 0.127 | F(2, 24) = 2.26 | 0.16 | 0.127 | F(2, 27) = 2.91 | 0.18 | 0.072 | F(2, 24) = 2.26 | 0.16 | 0.127 |
Examination | F(1, 24) = 0.53 | 0.02 | 0.472 | F(1, 24) = 0.53 | 0.02 | 0.472 | F(1, 27) = 0.46 | 0.02 | 0.504 | F(1, 24) = 0.53 | 0.02 | 0.472 |
Group:Examination | F(2, 24) = 6.69 | 0.36 | 0.005 | F(2, 24) = 6.69 | 0.36 | 0.005 | F(2, 27) = 8.00 | 0.37 | 0.002 | F(2, 24) = 6.69 | 0.36 | 0.005 |
Figure 11: Box & violon plots of EF(M) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 60.33 (8.30) | 59.81 (1.15) | 60.50 (45.00, 76.67) |
Post | 70.92 (7.75) | 70.52 (1.12) | 74.00 (57.33, 80.00) | |
p-value: | 0.057 | 0.027 | ||
p-value (imputed): | 0.057 | 0.057 | ||
50mg DFP | Pre | 77.90 (4.66) | 77.78 (1.06) | 76.33 (71.00, 85.67) |
Post | 61.75 (13.45) | 60.44 (1.25) | 60.67 (43.00, 77.67) | |
p-value: | 0.004 | 0.003 | ||
p-value (imputed): | 0.004 | 0.004 | ||
100mg DFP | Pre | 71.90 (11.59) | 71.10 (1.17) | 70.21 (58.67, 95.67) |
Post | 70.50 (7.89) | 70.10 (1.12) | 69.50 (57.33, 83.00) | |
p-value: | 0.772 | 0.838 | ||
p-value (imputed): | 0.772 | 0.772 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 70.04 (11.17) | 69.16 (1.18) | 70.83 (45.00, 95.67) | |
control | 60.33 (8.30) | 59.81 (1.15) | 60.50 (45.00, 76.67) | ||
50mg DFP | 77.90 (4.66) | 77.78 (1.06) | 76.33 (71.00, 85.67) | ||
100mg DFP | 71.90 (11.59) | 71.10 (1.17) | 70.21 (58.67, 95.67) | ||
p-value: | control vs. 50mg DFP | 0.001 | <0.001 | ||
p-value (imputed): | control vs. 50mg DFP | 0.001 | 0.001 | ||
p-value: | control vs. 100mg DFP | 0.038 | 0.019 | ||
p-value (imputed): | control vs. 100mg DFP | 0.038 | 0.038 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.314 | 0.318 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.314 | 0.314 | ||
Post | (overall) | 68.05 (10.30) | 67.22 (1.18) | 69.67 (43.00, 83.00) | |
control | 70.92 (7.75) | 70.52 (1.12) | 74.00 (57.33, 80.00) | ||
50mg DFP | 61.75 (13.45) | 60.44 (1.25) | 60.67 (43.00, 77.67) | ||
100mg DFP | 70.50 (7.89) | 70.10 (1.12) | 69.50 (57.33, 83.00) | ||
p-value: | control vs. 50mg DFP | 0.125 | 0.107 | ||
p-value (imputed): | control vs. 50mg DFP | 0.125 | 0.125 | ||
p-value: | control vs. 100mg DFP | 0.995 | 0.999 | ||
p-value (imputed): | control vs. 100mg DFP | 0.995 | 0.995 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.136 | 0.118 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.136 | 0.136 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 24: Summary statistics: EF(A2C).
EF(A2C) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: EF(A2C) (Shapiro-Wilk normality test: p=0.242) | |||
(total) | 57 (100.0%) | 72.71 ±8.3 | 73.5 (47.8:87.6) |
Grup: Group (ANOVA: p=0.548) | |||
before induction | 30 (52.6%) | 74.15 ±9.8 | 77.5 (47.8:87.6) |
control | 9 (15.8%) | 70.25 ±6.7 | 72.9 (54.8:76.2) |
50mg DFP | 8 (14.0%) | 72.28 ±7.1 | 73.6 (61.6:84.3) |
100mg DFP | 10 (17.5%) | 70.92 ±5.0 | 70.9 (62.7:78.4) |
Figure 13: Box & violon plots of EF(A2C) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 25: ANOVA model: EF(A2C).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 150.5 | 0.715 | 0.548 |
Group: untreated vs. treated | 1 | 37.0 | 0.526 | 0.471 |
Group: no HF vs. no control | 1 | 105.3 | 1.500 | 0.226 |
Group: 50 vs. 100 mg DFP | 1 | 8.3 | 0.118 | 0.733 |
Residuals | 53 | 3 721.5 |
|
Figure 14: Box & violon plots of EF(A2C) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 26: ANOVA model: EF(A2C).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 150.5 | 0.715 | 0.548 |
Group: no HF vs. HF | 1 | 132.6 | 1.889 | 0.175 |
Group: control vs. treated | 1 | 9.6 | 0.137 | 0.712 |
Group: 50 vs. 100 mg DFP | 1 | 8.3 | 0.118 | 0.733 |
Residuals | 53 | 3 721.5 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 24) = 4 047.56 | 0.99 | <0.001 | F(1, 24) = 4 047.56 | 0.99 | <0.001 | F(1, 27) = 79 325.51 | 1.00 | <0.001 | F(1, 24) = 4 047.56 | 0.99 | <0.001 |
Group | F(2, 24) = 3.03 | 0.20 | 0.067 | F(2, 24) = 3.03 | 0.20 | 0.067 | F(2, 27) = 3.28 | 0.20 | 0.053 | F(2, 24) = 3.03 | 0.20 | 0.067 |
Examination | F(1, 24) = 2.71 | 0.10 | 0.113 | F(1, 24) = 2.71 | 0.10 | 0.113 | F(1, 27) = 1.71 | 0.06 | 0.202 | F(1, 24) = 2.71 | 0.10 | 0.113 |
Group:Examination | F(2, 24) = 2.39 | 0.17 | 0.113 | F(2, 24) = 2.39 | 0.17 | 0.113 | F(2, 27) = 2.49 | 0.16 | 0.102 | F(2, 24) = 2.39 | 0.17 | 0.113 |
Figure 13: Box & violon plots of EF(A2C) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 67.82 (11.58) | 66.89 (1.19) | 67.72 (47.84, 85.26) |
Post | 70.25 (6.68) | 69.94 (1.11) | 72.89 (54.78, 76.23) | |
p-value: | 0.436 | 0.304 | ||
p-value (imputed): | 0.436 | 0.436 | ||
50mg DFP | Pre | 78.71 (6.37) | 78.47 (1.09) | 78.99 (65.78, 87.62) |
Post | 72.28 (7.06) | 71.98 (1.10) | 73.56 (61.63, 84.27) | |
p-value: | 0.049 | 0.071 | ||
p-value (imputed): | 0.049 | 0.049 | ||
100mg DFP | Pre | 75.93 (8.02) | 75.53 (1.12) | 78.24 (60.76, 84.56) |
Post | 70.92 (5.01) | 70.76 (1.07) | 70.95 (62.69, 78.36) | |
p-value: | 0.122 | 0.164 | ||
p-value (imputed): | 0.122 | 0.122 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 74.15 (9.81) | 73.46 (1.15) | 77.53 (47.84, 87.62) | |
control | 67.82 (11.58) | 66.89 (1.19) | 67.72 (47.84, 85.26) | ||
50mg DFP | 78.71 (6.37) | 78.47 (1.09) | 78.99 (65.78, 87.62) | ||
100mg DFP | 75.93 (8.02) | 75.53 (1.12) | 78.24 (60.76, 84.56) | ||
p-value: | control vs. 50mg DFP | 0.008 | 0.006 | ||
p-value (imputed): | control vs. 50mg DFP | 0.008 | 0.008 | ||
p-value: | control vs. 100mg DFP | 0.061 | 0.044 | ||
p-value (imputed): | control vs. 100mg DFP | 0.061 | 0.061 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.595 | 0.719 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.595 | 0.595 | ||
Post | (overall) | 71.10 (6.04) | 70.84 (1.09) | 71.22 (54.78, 84.27) | |
control | 70.25 (6.68) | 69.94 (1.11) | 72.89 (54.78, 76.23) | ||
50mg DFP | 72.28 (7.06) | 71.98 (1.10) | 73.56 (61.63, 84.27) | ||
100mg DFP | 70.92 (5.01) | 70.76 (1.07) | 70.95 (62.69, 78.36) | ||
p-value: | control vs. 50mg DFP | 0.852 | 0.857 | ||
p-value (imputed): | control vs. 50mg DFP | 0.852 | 0.852 | ||
p-value: | control vs. 100mg DFP | 0.981 | 0.984 | ||
p-value (imputed): | control vs. 100mg DFP | 0.981 | 0.981 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.927 | 0.931 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.927 | 0.927 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 27: Summary statistics: Weight (g).
Weight (g) | N (%) | Mean ±SD | Median (Min:Max) |
Grup: Weight (g) (Shapiro-Wilk normality test: p=0.485) | |||
(total) | 60 (100.0%) | 240.90 ±19.2 | 243.5 (193.0:296.0) |
Grup: Group (ANOVA: p<0.001) | |||
before induction | 30 (50.0%) | 234.93 ±16.4 | 237.5 (210.0:280.0) |
control | 10 (16.7%) | 226.70 ±16.9 | 230.0 (193.0:245.0) |
50mg DFP | 10 (16.7%) | 256.30 ±5.6 | 255.0 (249.0:265.0) |
100mg DFP | 10 (16.7%) | 257.60 ±18.0 | 255.0 (240.0:296.0) |
Figure 15: Box & violon plots of Weight (g) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 28: ANOVA model: Weight (g).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 8 244.9 | 11.360 | <0.001 *** |
Group: untreated vs. treated | 1 | 7 728.1 | 31.943 | <0.001 *** |
Group: no HF vs. no control | 1 | 508.4 | 2.101 | 0.153 |
Group: 50 vs. 100 mg DFP | 1 | 8.5 | 0.035 | 0.852 |
Residuals | 56 | 13 548.5 |
|
Figure 16: Box & violon plots of Weight (g) by group. p-values from planned contrasts comparrisons of each group with all combined groups to the right. Diamonds denote means. Dotted line is the overall mean.
Table 29: ANOVA model: Weight (g).
Effect: planned contrasts | DF | SSq | F | p (signif.) |
Group | 3 | 8 244.9 | 11.360 | <0.001 *** |
Group: no HF vs. HF | 1 | 2 136.1 | 8.829 | 0.004 ** |
Group: control vs. treated | 1 | 6 100.4 | 25.215 | <0.001 *** |
Group: 50 vs. 100 mg DFP | 1 | 8.4 | 0.035 | 0.852 |
Residuals | 56 | 13 548.5 |
|
Table 4: Two Repeated measures ANOVA models: linear, with raw data and log, with log-transformed data.
Transformation: | None (Linear scale): | Log base 10 scale: | ||||||||||
Missing data: | Removed: | Imputed: | Removed: | Imputed: | ||||||||
Effect | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value | F (DF) | Partial Eta² | p-value |
(Intercept) | F(1, 27) = 12 130.10 | 1.00 | <0.001 | F(1, 27) = 12 130.10 | 1.00 | <0.001 | F(1, 27) = 385 830.68 | 1.00 | <0.001 | F(1, 27) = 12 130.10 | 1.00 | <0.001 |
Group | F(2, 27) = 7.68 | 0.36 | 0.002 | F(2, 27) = 7.68 | 0.36 | 0.002 | F(2, 27) = 8.30 | 0.38 | 0.002 | F(2, 27) = 7.68 | 0.36 | 0.002 |
Examination | F(1, 27) = 10.55 | 0.28 | 0.003 | F(1, 27) = 10.55 | 0.28 | 0.003 | F(1, 27) = 9.03 | 0.25 | 0.006 | F(1, 27) = 10.55 | 0.28 | 0.003 |
Group:Examination | F(2, 27) = 5.01 | 0.27 | 0.014 | F(2, 27) = 5.01 | 0.27 | 0.014 | F(2, 27) = 4.52 | 0.25 | 0.020 | F(2, 27) = 5.01 | 0.27 | 0.014 |
Figure 15: Box & violon plots of Weight (g) by group. p-values from planned contrasts comparrisons. Diamonds denote means. Dotted line is the overall mean.
Table 5: Average NTproBNP values for all groups, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Group | Examination | Mean (SD) | Geometric mean | Median (Range) |
control | Pre | 231.10 (16.33) | 230.57 (1.07) | 241.50 (210.00, 245.00) |
Post | 226.70 (16.85) | 226.12 (1.08) | 230.00 (193.00, 245.00) | |
p-value: | 0.495 | 0.492 | ||
p-value (imputed): | 0.495 | 0.495 | ||
50mg DFP | Pre | 234.50 (15.06) | 234.07 (1.07) | 233.00 (213.00, 258.00) |
Post | 256.30 (5.58) | 256.25 (1.02) | 255.00 (249.00, 265.00) | |
p-value: | 0.002 | 0.003 | ||
p-value (imputed): | 0.002 | 0.002 | ||
100mg DFP | Pre | 239.20 (18.37) | 238.59 (1.08) | 238.50 (220.00, 280.00) |
Post | 257.60 (17.96) | 257.06 (1.07) | 255.00 (240.00, 296.00) | |
p-value: | 0.007 | 0.013 | ||
p-value (imputed): | 0.007 | 0.007 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |
Table 6: Average NTproBNP values for each group, at both initial and final measurements. We privided regular means and SDs (with p-values from the raw data model), geometric means and SDs (with p-values from the log-transfomed data model) and medians with ranges.
Examination | Comparrison | Group | Mean (SD) | Geometric mean | Median (Range) |
Pre | (overall) | 234.93 (16.41) | 234.39 (1.07) | 237.50 (210.00, 280.00) | |
control | 231.10 (16.33) | 230.57 (1.07) | 241.50 (210.00, 245.00) | ||
50mg DFP | 234.50 (15.06) | 234.07 (1.07) | 233.00 (213.00, 258.00) | ||
100mg DFP | 239.20 (18.37) | 238.59 (1.08) | 238.50 (220.00, 280.00) | ||
p-value: | control vs. 50mg DFP | 0.878 | 0.865 | ||
p-value (imputed): | control vs. 50mg DFP | 0.878 | 0.878 | ||
p-value: | control vs. 100mg DFP | 0.484 | 0.478 | ||
p-value (imputed): | control vs. 100mg DFP | 0.484 | 0.484 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.781 | 0.791 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.781 | 0.781 | ||
Post | (overall) | 246.87 (20.21) | 246.04 (1.09) | 249.50 (193.00, 296.00) | |
control | 226.70 (16.85) | 226.12 (1.08) | 230.00 (193.00, 245.00) | ||
50mg DFP | 256.30 (5.58) | 256.25 (1.02) | 255.00 (249.00, 265.00) | ||
100mg DFP | 257.60 (17.96) | 257.06 (1.07) | 255.00 (240.00, 296.00) | ||
p-value: | control vs. 50mg DFP | <0.001 | <0.001 | ||
p-value (imputed): | control vs. 50mg DFP | <0.001 | <0.001 | ||
p-value: | control vs. 100mg DFP | <0.001 | <0.001 | ||
p-value (imputed): | control vs. 100mg DFP | <0.001 | <0.001 | ||
p-value: | 50mg DFP vs. 100mg DFP | 0.981 | 0.994 | ||
p-value (imputed): | 50mg DFP vs. 100mg DFP | 0.981 | 0.981 | ||
P-values are computed from the raw data model for the means and from log-transformed data model for the geometric means. |